SCHEMBL3564263

SCHEMBL3564263

COc1ccc(C=CC(=O)N2CC(CCl)c3c2cc([N+](=O)[O-])c2cc(S(N)(=O)=O)ccc32)cc1O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.45
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
CA2 P00918 3/20 0.39
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 3/20 0.38
APP P05067 1/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA9 Q16790 2/20 0.37
CA4 P22748 1/20 0.37
POLB P06746 1/20 0.37
TOP2A P11388 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564259 1.00 BACE1 (0.45) BACE1ALDH1A1LMNAHPGDCA2
SCHEMBL3563244 0.80 BACE1 (0.37) BACE1ALDH1A1LMNAKMT2AMAPT
SCHEMBL3563247 0.80 BACE1 (0.37) BACE1ALDH1A1LMNAKMT2AMAPT
SCHEMBL4182123 0.79 ALDH1A1 (0.36) ALDH1A1LMNAKMT2AKDM4EMAPT
SCHEMBL13853316 0.79 MAPK1 (0.34) BACE1ALDH1A1LMNAKMT2AKDM4E
SCHEMBL5624641 0.77 ALDH1A1 (0.44) BACE1ALDH1A1LMNAKMT2AMAPT
SCHEMBL5624650 0.77 ALDH1A1 (0.44) BACE1ALDH1A1LMNAKMT2AMAPT
SCHEMBL3557000 0.77 P4HB (0.49) ALDH1A1LMNAHPGDCA2KMT2A
SCHEMBL13853314 0.77 LMNA (0.45) ALDH1A1LMNACA2KMT2AKDM4E
SCHEMBL3562214 0.77 CA2 (0.42) ALDH1A1LMNACA2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US claimed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US claimed
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A BACE1 3611/4885ALDH1A1 77/4885LMNA 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.